4564.T
Price:
$21
Market Cap:
$7.11B
OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as...[Read more]
Industry
Biotechnology
IPO Date
2005-09-29
Stock Exchange
JPX
Ticker
4564.T
According to OncoTherapy Science, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -7.42. This represents a change of -36.31% compared to the average of -11.65 of the last 4 quarters.
The mean historical PE Ratio of OncoTherapy Science, Inc. over the last ten years is -9.04. The current -7.42 PE Ratio has changed 8.11% with respect to the historical average. Over the past ten years (40 quarters), 4564.T's PE Ratio was at its highest in in the March 2024 quarter at -3.62. The PE Ratio was at its lowest in in the June 2020 quarter at -20.18.
Average
-9.04
Median
-8.53
Minimum
-16.81
Maximum
-3.30
Discovering the peaks and valleys of OncoTherapy Science, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 207.55%
Maximum Annual PE Ratio = -3.30
Minimum Annual Increase = -63.78%
Minimum Annual PE Ratio = -16.81
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -8.97 | 171.47% |
| 2024 | -3.30 | -59.18% |
| 2023 | -8.09 | 60.91% |
| 2022 | -5.03 | -63.78% |
| 2021 | -13.89 | 207.55% |
| 2020 | -4.52 | -32.94% |
| 2019 | -6.73 | -38.98% |
| 2018 | -11.04 | -8.02% |
| 2017 | -12.00 | -28.64% |
| 2016 | -16.81 | -59.33% |
The current PE Ratio of OncoTherapy Science, Inc. (4564.T) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-6.79
5-year avg
-7.86
10-year avg
-9.04
OncoTherapy Science, Inc.’s PE Ratio is greater than K Pharma,Inc. (-8.59), less than BrightPath Biotherapeutics Co., Ltd. (-4.40), less than ADR120S, Inc. (-4.07), greater than Noile-Immune Biotech Inc. (-10.07), greater than TMS Co., Ltd. (-8.13), greater than Linical Co., Ltd. (-10.76), greater than Chiome Bioscience Inc. (-7.56), less than MedRx Co., Ltd (-4.39), less than Kohjin Bio Co., Ltd. (11.15), less than Delta-Fly Pharma, Inc. (-3.35),
| Company | PE Ratio | Market cap |
|---|---|---|
| -8.59 | $7.43B | |
| -4.40 | $4.63B | |
| -4.07 | $7.44B | |
| -10.07 | $6.97B | |
| -8.13 | $6.10B | |
| -10.76 | $6.82B | |
| -7.56 | $7.55B | |
| -4.39 | $6.53B | |
| 11.15 | $7.96B | |
| -3.35 | $5.91B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like OncoTherapy Science, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like OncoTherapy Science, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is OncoTherapy Science, Inc.'s PE Ratio?
How is the PE Ratio calculated for OncoTherapy Science, Inc. (4564.T)?
What is the highest PE Ratio for OncoTherapy Science, Inc. (4564.T)?
What is the 3-year average PE Ratio for OncoTherapy Science, Inc. (4564.T)?
What is the 5-year average PE Ratio for OncoTherapy Science, Inc. (4564.T)?
How does the current PE Ratio for OncoTherapy Science, Inc. (4564.T) compare to its historical average?